NVCR FINANCIAL STATEMENTS

Novocure Ltd — balance sheet, income statement and cash flow trends

NVCRNovocure Ltd

🇺🇸 USA · NASDAQ · Healthcare · Medical Devices

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue674.4 M $+8.5%

Gross Profit507.1 M $+5.7%

Operating Income-183.4 M $—

EBITDA-155.4 M $—

Net Income-173 M $—

Peer Comparison· Medical Devices

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
NVCR	8.5%	75.2%	-23.0%	-25.7%
4DX	-26.0%	-396.6%	-818.8%	-3,684.6%
COH	2.0%	73.0%	24.0%	14.6%
SN	—	68.0%	25.6%	10.1%
PHIA	-1.9%	45.2%	15.4%	5.5%
ONCSM	39.1%	48.4%	30.6%	6.3%
Industry median	7.4%	58.9%	5.2%	-5.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
NVCR	8.5%	75.2%	-23.0%	-25.7%
BFLY	20.2%	49.2%	-64.8%	-73.6%
NEOG	-3.9%	42.6%	-51.5%	-69.9%
UFPT	11.2%	28.4%	19.1%	11.3%
AXGN	22.4%	75.0%	-3.5%	-13.2%
TMDX	30.2%	59.1%	22.0%	27.0%
Industry median	7.4%	58.9%	5.2%	-5.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity330.7 M $42%
Current Liabilities217.6 M $28%
Long-term Liabilities239.6 M $30%

Key Figures

YoY change

Total Assets787.9 M $-36.9%

Total Liabilities457.2 M $-48.4%

Total Equity330.7 M $-8.6%

Cash & ST Investments441.8 M $-52.6%

Total Debt234.9 M $-66.3%

Net Debt137.6 M $-75.8%

Peer Comparison· Medical Devices

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
NVCR	2.90	71.0%	1.33	42.0%
4DX	6.57	-22.6%	0.71	-20.4%
COH	2.46	22.1%	0.42	69.4%
SN	2.57	62.9%	1.72	50.6%
PHIA	1.32	71.1%	2.03	41.8%
ONCSM	2.25	35.0%	0.42	56.4%
Industry median	3.28	44.7%	0.82	49.7%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
NVCR	2.90	71.0%	1.33	42.0%
BFLY	4.02	10.3%	1.77	66.9%
NEOG	3.92	37.7%	-1.41	62.6%
UFPT	2.91	35.6%	1.17	65.0%
AXGN	7.10	8.4%	7.53	84.6%
TMDX	6.74	174.8%	2.87	34.4%
Industry median	3.28	44.7%	0.82	49.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-26.9 M $—

Capital Expenditures21.2 M $-49.2%

Free Cash Flow-48.1 M $—

Dividends Paid——

Peer Comparison· Medical Devices

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
NVCR	-4.0%	-7.1%	3.1%	15.5%
4DX	-761.6%	-530.7%	3.7%	20.7%
COH	11.2%	8.5%	2.7%	76.6%
SN	20.8%	13.8%	7.0%	205.6%
PHIA	13.0%	10.8%	2.2%	236.4%
ONCSM	6.2%	-5.5%	12.0%	99.3%
Industry median	7.2%	1.5%	4.1%	76.6%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
NVCR	-4.0%	-7.1%	3.1%	15.5%
BFLY	-14.5%	-18.3%	3.8%	19.7%
NEOG	8.0%	4.8%	8.7%	-11.4%
UFPT	13.4%	11.4%	1.9%	118.5%
AXGN	6.5%	3.8%	2.8%	-49.5%
TMDX	34.6%	23.8%	10.8%	128.1%
Industry median	7.2%	1.5%	4.1%	76.6%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on NVCR

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.